DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Rebif (Interferon Beta-1a) - Drug Interactions, Contraindications, Overdosage, etc



No formal drug interaction studies have been conducted with Rebif® . Due to its potential to cause neutropenia and lymphopenia, proper monitoring of patients is required if Rebif® is given in combination with myelosuppressive agents.


Safety of doses higher than 44 mcg sc tiw has not been adequately evaluated. The maximum amount of Rebif® that can be safely administered has not been determined.


Rebif® (interferon beta-1a) is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon, human albumin, or any other component of the formulation.


  1. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon (beta)-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
  2. Data on file.

Manufacturer: Serono, Inc. Rockland, MA 02370

U.S. License # 1574

Co-Marketed by:

Serono, Inc.

Rockland, MA 02370

Pfizer Inc.

New York, NY 10017

Revised: March 2004

* Avonex® is a registered trademark of Biogen, Inc.

N6700101B                                                   04/04











-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015